Abbvie-Header Abbvie-Header


Find Clinical Drug Development Pipelines & Deals | PipelineProspector


All Data

Filters Filter refresh
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Rho-associated kinase-Human corneal endothelial cells

            Therapeutic Area: Ophthalmology Product Name: AE101

            Highest Development Status: Preclinical Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Arctic Vision

            Deal Size: $35.0 million Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement May 14, 2021


            Arctic Vision will develop and market ActualEyes’ AE-101, for the treatment of corneal endothelial dysfunction in Greater China and South Korea. ARVN901 (AE-101) is a novel cell-injection therapy developed using cultured hCECs combined with a ROCK inhibitor.